Search Results for "anaerobic"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for anaerobic. Results 1 to 3 of 3 total matches.

Drugs for Acute Otitis Media in Children

   
The Medical Letter on Drugs and Therapeutics • Feb 07, 2022  (Issue 1643)
, and anaerobic bacteria are less common causes. AOM is also frequently associated with viral respiratory ...
More antibiotics are prescribed for treatment of acute otitis media (AOM) than for any other infection in young children. Children with AOM typically present with otalgia, fever, and bulging and erythema of the tympanic membrane.
Med Lett Drugs Ther. 2022 Feb 7;64(1643):22-3 |  Show IntroductionHide Introduction

Ceftobiprole Medocaril (Zevtera) — A New Cephalosporin Antibiotic

   
The Medical Letter on Drugs and Therapeutics • Sep 15, 2025  (Issue 1737)
polymicrobial; they can be caused by anaerobes and gram-negative bacilli, such as Escherichia coli ...
Ceftobiprole medocaril sodium (Zevtera – Innoviva Specialty Therapeutics), a new IV cephalosporin antibacterial drug, has been approved by the FDA for treatment of Staphylococcus aureus bacteremia (SAB), including right-sided infective endocarditis, acute bacterial skin and skin structure infections (ABSSSIs), and community-acquired bacterial pneumonia (CABP) (see Table 1). It is the second cephalosporin with activity against methicillin-resistant S. aureus (MRSA) to be approved in the US; ceftaroline (Teflaro), which was approved for treatment of ABSSSIs and CABP in 2010, was the...
Med Lett Drugs Ther. 2025 Sep 15;67(1737):149-52   doi:10.58347/tml.2025.1737d |  Show IntroductionHide Introduction

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
and anaerobic bacteria may also be involved as secondary pathogens. Data on the etiologic role of M ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 |  Show IntroductionHide Introduction